



European
Crohn's and Colitis
Organisation

Berlin
Germany

Inflammatory Bowel Diseases

Pocket Guide



20th Congress of ECCO
CityCube Messe Berlin
February 19 - 22, 2025

www.ecco-ibd.eu

Opening hours

Cloakroom

Tuesday, February 18, 2025	closed
Wednesday, February 19, 2025	07:00 - 21:30
Thursday, February 20, 2025	07:00 - 21:30
Friday, February 21, 2025	06:45 - 20:30
Saturday, February 22, 2025	08:00 - 14:00

Speakers' Centre

Tuesday, February 18, 2025	16:00 - 19:00
Wednesday, February 19, 2025	07:00 - 18:00
Thursday, February 20, 2025	07:00 - 19:30
Friday, February 21, 2025	06:45 - 19:30
Saturday, February 22, 2025	08:00 - 14:00

ECCO Registration Desk

Tuesday, February 18, 2025	14:00 - 18:00
Wednesday, February 19, 2025	07:00 - 18:00
Thursday, February 20, 2025	07:00 - 19:00
Friday, February 21, 2025	07:00 - 19:00
Saturday, February 22, 2025	08:00 - 13:30

ECCO Booth

Wednesday, February 19, 2025	07:00 - 18:00
Thursday, February 20, 2025	07:00 - 19:00
Friday, February 21, 2025	07:00 - 19:00
Saturday, February 22, 2025	08:00 - 14:00

Members' Lounge, Industry Exhibition & Poster Exhibition

Wednesday, February 19, 2025	closed
Thursday, February 20, 2025	10:30 - 18:00
Friday, February 21, 2025	08:00 - 18:00
Saturday, February 22, 2025	09:00 - 13:00

e-Learning Forum: Level Up Your Learning



Don't miss our special **e-Learning Forum** event!


What to Expect:

- **Drop-in Flexibility:** Join us for as long or as short as you'd like
- **Interactive Demonstrations:** Get hands-on experience with our e-Learning Platform on touchscreen kiosks
- **Expert Presentations:** Learn directly from our e-Learning Taskforce


We look forward to seeing you there!

Thursday, February 20th
8:00 am - 12:00 pm
Room: London 1

General floorplan



ECCO 2025 Congress Map



"Sustainability in IBD and beyond"

Thursday, February 20, 2025

Scientific programme day by day (as of January 23, 2025)
Plenary Hall/Hall B, CityCube Messe Berlin

CME accreditation: 14 CME credits

Thursday Kick-off

11:00 - 12:00	Industry sponsored satellite symposia 1a, 1b, 1c, 1d, 1e
12:00 - 12:15	Break
12:15 - 12:30	1: Opening B. Siegmund, Berlin, Germany

Thursday afternoon – Session 1

12:30 - 14:00	Scientific Session 1: Sustainability in IBD Care R. Dart, London, United Kingdom S. Restellini, Geneva, Switzerland
12:30 - 12:50	2: Novel strategies to achieve a sustainable treatment E. Louis, Liège, Belgium
12:50 - 13:00	3: OP01 – Systemic antibody responses predict the onset of Inflammatory Bowel Disease up to 10 years before diagnosis A.R. Bourgonje, New York, United States
13:00 - 13:20	4: Impact of lifestyle to sustain health and prevent IBD R. Banerjee, Hyderabad, India
13:20 - 13:30	5: OP02 – Tasty&Healthy flexible diet induces clinical and biological remission in children and young adults with mild-moderate Crohn's Disease similar to EEN: Results from the "TASTI-MM" randomized, physician-blinded, controlled trial L. Plotkin, Netanya, Israel
13:30 - 13:40	6: OP03 – Mapping the observable IBDverse: Using massive-scale single-cell RNA sequencing of gut and blood samples to nominate genes, cell types and pathways driving IBD susceptibility B. Harris, Cambridge, United Kingdom

OP = Oral presentation – best abstracts

13:40 - 14:00	7: ESPGHAN-ECCO UC Guidelines update A. Assa, Jerusalem, Israel E. Wine, Edmonton, Canada
14:00 - 14:30	Coffee break
14:00 - 14:20	Industry sponsored Medical/Product Theatre PT1 & PT2
Thursday afternoon – Session 2	
14:30 - 16:00	Scientific Session 2: Novelties in IBD Care D. Duricova, Prague, Czech Republic M. Samaan, London, United Kingdom
14:30 - 15:10	8: IBD care in 2025: Novel Drugs – S. Danese, Milan, Italy Selection of Drugs – T. Lobaton, Ghent, Belgium Strategies – M. Parkes, Cambridge, United Kingdom
15:10 - 15:20	9: OP04 – Multi-omics biomarkers for predicting therapeutic efficacy in Inflammatory Bowel Disease: Advancing towards tailored treatments M. Baldan-Martin, Madrid, Spain
15:20 - 15:30	10: OP05 – Efficacy and safety of autologous hematopoietic stem cell transplantation in refractory Crohn's Disease: Outcomes from the international stem cell transplant consortium D. Guisado, New York, United States
15:30 - 15:40	11: OP06 – HLA-DQA1*05:01 is associated with loss of response to infliximab, and HLA DQA1*05:05 with loss of response to adalimumab in the Oxford OASIS study N. Ternette, Oxford, United Kingdom
15:40 - 16:00	12: ChatGPT, Dr. Google – helpful or harmful? S. Ben-Horin, Tel Aviv, Israel
16:00 - 16:10	Break

Thursday, February 20, 2025, cont.

Scientific programme day by day (as of January 23, 2025)
Plenary Hall/Hall B, CityCube Messe Berlin

Thursday afternoon – Session 3

16:10 - 17:30	Scientific Session 3: Sustaining Remission – a joint effort R. Atreya, Erlangen, Germany V. Solitano, Milan, Italy
16:10 - 16:30	13: Sustainable classification of IBD D. McGovern, Los Angeles, United States
16:30 - 16:50	14: Tandem Talk: Strategies to improve adherence to therapy C. Hedin, Stockholm, Sweden S. Jäghult, Stockholm, Sweden
16:50 - 17:00	15: OP07 – Psychosocial factors are associated with risk of flare in IBD; Results from the PREdiCCt study L. Derikx, Rotterdam, The Netherlands
17:00 - 17:10	16: OP08 – Histology-derived cell-cell interaction networks, linked to transcriptome profiling, define path to resolution in UC D. Dylus, Basel, Switzerland
17:10 - 17:30	17: How should we currently measure and define long-term remission? Y. Zabana, Terrassa, Spain
17:30 - 17:45	Break
17:45 - 18:45	Digital Oral Presentations (Sessions 1-5) See pg. 17
18:45 - 19:00	Break
19:00 - 20:00	Industry Sponsored Satellite Symposia 2a, 2d

OP = Oral presentation – best abstracts

Friday, February 21, 2025

Scientific programme day by day (as of January 23, 2025)
Plenary Hall/Hall B, CityCube Messe Berlin

Friday morning – Session 4

08:30 - 09:30	Digital Oral Presentations (Sessions 6-10) See pg. 18
09:30 - 09:45	Break
09:45 - 10:35	Scientific Session 4: Novel Monitoring Tools N. Noor, Cambridge, United Kingdom M. Pierik, Maastricht, Netherlands
09:45 - 10:05	18: From Biomarkers to AI Monitoring B. Verstockt, Leuven, Belgium
10:05 - 10:15	19: OP09 – Dose intensification of vedolizumab is not effective in inducing endoscopic response in Crohn's Disease patients with endoscopic primary non-response L. Oldenburg, Amsterdam, The Netherlands
10:15 - 10:25	20: OP10 – Efficacy and safety of subcutaneous guselkumab induction therapy in patients with Ulcerative Colitis: Results through week 12 from the phase 3 ASTRO study L. Peyrin-Biroulet, Vandoeuvre-Lès-Nancy, France
10:25 - 10:35	21: OP11 – Analysing the T cell receptor beta chain repertoire of 2,800 Inflammatory Bowel Disease patients identifies public T cell responses involved in the pathogenesis of Crohn's Disease and Ulcerative Colitis and quantifies the impact of surgery and therapy on the immune repertoire of IBD patients H. Elabd, Kiel, Germany
10:35 - 11:00	Break
10:35 - 10:55	Industry Sponsored Medical/Product Theatre PT3, PT4

OP = Oral presentation – best abstracts

Friday, February 21, 2025, cont.

Scientific programme day by day (as of January 23, 2025)
Plenary Hall/Hall B, CityCube Messe Berlin

Friday morning – Session 5

11:00 - 12:30	Scientific Session 5: Sustainable Technology and Consequences: ESGE-ECCO collaborative session on endoscopy R. Bisschops, Leuven, Belgium G. Dragoni, Florence, Italy
11:00 - 11:20	22: Novel technologies in endoscopy: is there an additive benefit in patients with IBD? R. Bisschops, Leuven, Belgium
11:20 - 11:30	23: OP12 – Therapeutic antibody clearance better predicts endoscopic outcomes than trough concentrations in patients with Crohn's Disease E. Dreesen, Leuven, Belgium
11:30 - 11:50	24: The role of endoscopy in the era of biomarkers B. Ungar, Ramat Gan, Israel
11:50 - 12:00	25: OP13 – Higher neoplasia detection rate and lower number of targeted biopsies associated with virtual chromoendoscopy in IBD surveillance: a real-world, multicentre UK study C. Radia, London, United Kingdom
12:00 - 12:10	26: OP14 – The United European Gastroenterology green paper – climate change and gastroenterology M. Duijvestein, Nijmegen, The Netherlands
12:10 - 12:30	27: Green endoscopy S. Sebastian, Hull, United Kingdom
12:30 - 13:40	Break
12:40 - 13:40	Guided Poster Session See pg. 20
12:45 - 13:25	Lunchtime Satellite Symposia LS1, LS2, LS3, LS4, LS5

OP = Oral presentation – best abstracts

Friday afternoon – Session 6

13:40 - 15:10	Scientific Session 6: Surgical Sustainability J. De Groof, Amsterdam, The Netherlands P. Myrelid, Linköping, Sweden
13:40 - 14:00	28: Tandem Talk: Mentally preparing the patient for IBD surgery O. Faiz, Harrow, United Kingdom T. Lores, New York, United States
14:00 - 14:10	29: OP15 – ECCO Topical Review on Pouch Disorders M. Kayal, New York, United States
14:10 - 14:30	30: The sustainable anastomosis – new insights about anastomotic healing Z. Lakkis, Besançon, France
14:30 - 14:40	31: OP16 – Postoperative endoscopic recurrence after ileocecal resection for Crohn's Disease with Kono-S or side-to-side functional end anastomosis: 12-18 months follow-up results from a multicenter prospective randomized trial K. Trencheva, New York, United States
14:40 - 14:50	32: OP17– Defining radiological healing in perianal fistulising Crohn's Disease: A global modified Delphi consensus E. Anand, London, United Kingdom
14:50 - 15:10	33: Tandem Talk: How do we define long-term success in surgery? C. Bezzio, Milan, Italy A. Spinelli, Milan, Italy
15:10 - 15:40	Coffee break

Friday, February 21, 2025, cont.

Scientific programme day by day (as of January 23, 2025)
Plenary Hall/Hall B, CityCube Messe Berlin

Friday afternoon – EITHER Sessions 7&8

15:40 - 16:20	Scientific Session 7: Nutritional News G. D'Arcangelo, Rome, Italy L. de Ridder, Rotterdam, The Netherlands
15:40 - 16:00	34: ECCO Consensus on Diet and Nutrition in IBD V. Svolos, Trikala, Greece R. Hansen, Dundee, United Kingdom
16:00- 16:10	35: OP18 – Multi-analytical approaches reveal robust gut microbial biomarkers for Inflammatory Bowel Disease diagnosis: A large-scale cohort study J-W. Choi, Seoul, Korea
16:10 - 16:20	36: OP19 – Pre- and post-diagnostic metabolomic biomarker profiling of over 700,000 individuals in three national biobanks enables prediction of Inflammatory Bowel Disease onset and complications A. Sazonovs, Copenhagen, Denmark
16:20 - 16:25	Break
16:25 - 17:25	Scientific Session 8: IBD Horizons M. Barnhoorn, Leiden, The Netherlands L. Gianolio, Edinburgh, United Kingdom
16:25 - 16:35	37: OP20 – Expanding the genetic spectrum of inflammatory bowel disease through large-scale exome sequencing Q. Zhang, Cambridge, United Kingdom
16:35 - 16:45	38: OP21 – MIF-CD74 signaling promotes intestinal LTI-like ILC3s activation and gut fibrosis via upregulating pSTAT3 Y. Zhao, Shanghai, China
16:45 - 16:55	39: OP22 – NR1D1 Deficiency induces CD47 upregulation impairing macrophage efferocytosis and exacerbating intestinal inflammation in Ulcerative Colitis Y. Chen, Wuhan, China
16:55 - 17:05	40: OP23 – Neutrophil niches and therapy resistance in Ulcerative Colitis: Spatial atlas insights S. Rogalla, Stanford, United States
17:05 - 17:15	41: OP24 – TL1A-activated T cells as upstream regulators of perianal fistulizing disease-associated changes in the rectum of Crohn's Disease patients V. Gudiño, Barcelona, Spain
17:15 - 17:25	42: OP25 – Young Researcher Award: Lymphocytic colitis can be transcriptionally divided into channelopathic and inflammatory lymphocytic colitis C. Escudero-Hernández, Kiel, Germany

OP = Oral presentation – best abstracts



Parallel Hall A7, CityCube Messe Berlin

Friday afternoon – OR Session 9

15:40 - 17:30	Scientific Session 9: Basic Science: Novel Genetic Insights I. Cleynen, Leuven, Belgium F. Tran, Kiel, Germany
15:40 - 16:00	43: Changing paradigms: trans-ethnic genetics in IBD across different groups D. McGovern, Los Angeles, United States
16:00 - 16:10	44: OP26 – Disentangling the role of HLA proteins in shaping the T-cell repertoire in Inflammatory Bowel Disease using CDR3-QTL analysis E. Lokes, Kiel, Germany
16:10 - 16:20	45: The role of somatic mutations in intestinal epithelial cells in IBD C. Anderson, Cambridge, United Kingdom
16:20 - 16:40	46: Environmental effects on spontaneous mutations – epigenetics J. Satsangi, Oxford, United Kingdom
16:40 - 16:50	47: OP27 – Unlocking Inflammatory Bowel Disease subtypes: A deep dive into transcriptomics and machine learning A. Acharjee, Birmingham, United Kingdom
16:50 - 17:00	48: OP28 – Anti-integrin $\alpha\text{v}\beta\text{6}$ autoantibodies are detected in preclinical, incident and established colonic Crohn's Disease A. Livanos, New York, United States
17:00 - 17:20	49: OP 29 – Young Researcher Award: Breaking new ground in IBD research: Organoid models as the vanguard for personalized therapies B. Verstockt, Leuven, Belgium
17:20 - 17:30	50: OP30 – Dissecting the genetic basis of clinical phenotype heterogeneity within IBD in more than 63,000 IBD patients D. McGovern, Los Angeles, United States
17:30 - 17:45	Break
17:45 - 18:45	Digital Oral Presentations (Sessions 11-15) See pg. 19
18:45 - 19:00	Break
19:00 - 20:00	Industry Sponsored Satellite Symposia 4a

OP = Oral presentation – best abstracts

Saturday, February 22, 2025

Scientific programme day by day (as of January 23, 2025)
Plenary Hall/Hall B, CityCube Messe Berlin

Saturday morning – Session 10

Scientific Session 10: Hot Topics in IBD	
08:10 - 10:20	G. Bamias, Athens, Greece J. Roseira, Portimao, Portugal
08:10 - 08:20	51: OP40 – Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active Crohn's Disease: results from a phase 2b, randomised, double-blind, placebo-controlled dose-ranging, basket trial (RELIEVE UCCD) V. Jairath, London, Canada
08:20 - 08:30	52: OP41 – Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active Ulcerative Colitis: Results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging, basket trial (RELIEVE UCCD) W. Reinisch, Vienna, Austria
08:30 - 08:50	53: Tandem Talk: How far should we pursue our targets to help patients live a normal life? I. Dotan, Petah Tikva, Israel R. Barkan, Petah Tikva, Israel
08:50 - 09:00	54: OP31 – Phase 1b study of SOR102, a novel, orally delivered bispecific anti-TNF/anti-IL-23 domain antibody in patients with mild to severe Ulcerative Colitis V. Jairath, London, Canada
09:00 - 09:20	55: OP32 – Identifying clusters of antibiotic use patterns after the first episode of pouchitis in a population-based cohort E. Barnes, Chapel Hill, United States
09:20 - 09:30	56: OP33 – Efficacy and safety of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn's Disease: Results through week 48 from the phase 3 GRAVITI study A. Hart, Harrow, United Kingdom
09:30 - 09:50	57: Multi-society Diagnostic Guidelines R. Feakins, London, United Kingdom T. Kucharzik, Lüneburg, Germany S. Taylor, London, United Kingdom

OP = Oral presentation – best abstracts

09:50 - 10:00	58: OP34 – Mirikizumab provides rapid improvements in bowel urgency severity, bowel urgency frequency, and stool deferral time in patients with moderately-to-severely active Ulcerative Colitis: 12-week interim results from the phase 3b LUCENT-URGE trial S. Danese, Milan, Italy
10:00 - 10:10	59: OP35 – Low remission recapture after ustekinumab dose optimization in Crohn's Disease: Results of the randomized placebo-controlled double-blind RESCUE study P. Bossuyt, Bonheiden, Belgium
10:10 - 10:20	60: OP36 – Lusvertikimab, a first-in-class IL7 receptor antagonist, in moderate to severe Ulcerative Colitis: Results of a multicenter, randomized, placebo-controlled phase II study A. Bourreille, Nantes Cedex, France
10:20 - 10:50	Coffee break

Saturday morning – Session 11

10:50 - 12:20	Scientific Session 11: Emerging Challenges M. Allez, Paris, France M. Estevinho, Vila Nova de Gaia, Portugal
10:50 - 11:10	61: Epidemiology in 2030 – prevalence, costs, climate change G. Kaplan, Calgary, Canada
11:10 - 11:20	62: OP37 – Delineating molecular and microbial signatures across disease severity in Inflammatory Bowel Disease in adult treatment naive patients through single-cell transcriptomic and microbiome profiling M. Leipner, Basel, Switzerland
11:20 - 11:40	63: Artificial Intelligence in Inflammatory Bowel Disease: today and tomorrow, conclusions from the 9th ECCO Scientific Workshop A. Mookhoek, Bern, Switzerland
11:40 - 11:50	64: OP38 – Comparative efficacy of infliximab and vedolizumab after failure of a first anti-TNF in patients with Ulcerative Colitis: A double-blind randomized controlled trial (EFFICACI) G. Bouguen, Rennes, France

Saturday, February 22, 2025, cont.

Scientific programme day by day (as of January 23, 2025)
Plenary Hall/Hall B, CityCube Messe Berlin

Saturday morning – Session 11 cont.

11:50 - 12:00	65: OP39 – Treatment with RO7790121 induces and maintains histologic and histologic-endoscopic improvement and remission in moderately to severely active Ulcerative Colitis – Results from TUSCANY-2 V. Jairath, London, Canada
12:00 - 12:20	66: ECCO Consensus on IBD in Low - and Middle - Income Countries A. El-Hussuna, Aalborg, Denmark

Saturday afternoon – Session 12

12:20 - 13:30	Scientific Session 12: ECCO Lecture B. Siegmund, Berlin, Germany F. Magro, Porto, Portugal
12:20 - 12:50	67: ECCO Lecture: Lean, green and clean – Sustainability in clinical practice and beyond C. Traidl-Hoffmann, Augsburg, Germany
12:50 - 13:20	68: Awards and closing remarks I. Cleynen, Leuven, Belgium
13:20 - 13:30	The ECCO Film

Digital oral presentations (DOP)

Thursday, February 20, 2025

A1, A4, A5, A7, A8

17:45 - 18:45 *Digital oral presentations Sessions 1-5*

Digital oral presentation Session 1	<i>Clinical Trials I</i> Room: Parallel Hall / A7 A. Armuzzi, Milan, Italy A. Centritto, London, United Kingdom
Digital oral presentation Session 2	<i>Clinical Trials II</i> Room: A8 R. Atreya, Erlangen, Germany M. Chaparro, Madrid, Spain
Digital oral presentation Session 3	<i>Microbiology and Virology in IBD</i> Room: A1 E. Wine, Edmonton, Canada C. Fidalgo, Lisbon, Portugal
Digital oral presentation Session 4	<i>Novel Targets in IBD</i> Room: A5 P. Borralho Nunes, Lisbon, Portugal A.R. Bourgonje, New York, United States
Digital oral presentation Session 5	<i>Epidemiology and Environment</i> Room: A4 R. Banerjee, Hyderabad, India J. Burisch, Hvidovre, Denmark

Friday, February 21, 2025

A1, A4, A5, A7, A8

08:30 - 09:30 *Digital oral presentations Sessions 6-10*

Digital oral presentation Session 6	Clinical Trials III Room: Parallel Hall / A7 I. Dotan, Petah Tikva, Israel C. Buskens, Amsterdam, The Netherlands
Digital oral presentation Session 7	Clinical Trials IV Room: A8 A. Dignass, Frankfurt, Germany D. Duricova, Praga, Czech Republic
Digital oral presentation Session 8	Translational IBD Room: A1 R. Dart, London, United Kingdom C. Reenaers, Liège, Belgium
Digital oral presentation Session 9	Diagnostics and Fibrosis in IBD Room: A5 M. Iacucci, Cork, Ireland F. Rieder, Cleveland, United States
Digital oral presentation Session 10	Clinical IBD Room: A4 S. Restellini, Geneva, Switzerland M. Samaan, London, United Kingdom

17:45 - 18:45 Digital oral presentations Sessions 11-15

Digital oral presentation Session 11	Clinical Trials V Room: Parallel Hall / A7 A. Sturm, Berlin, Germany J. van der Woude, Nijmegen, The Netherlands
Digital oral presentation Session 12	Clinical Trials and Diagnostics Room: A8 B. Verstockt, Leuven, Belgium M. Barreiro-de Acosta, Santiago De Compostela, Spain
Digital oral presentation Session 13	Basic Science in IBD Room: A1 M. Allez, Paris, France I. Arijis, Zaventem, Belgium
Digital oral presentation Session 14	Diagnostics, Biomarkers Room: A5 S. Mehandru, New York, United States H. Yanai, Tel Aviv, Israel
Digital oral presentation Session 15	Genetics and Multi-omics in IBD Room: A4 I. Cleynen, Leuven, Belgium M. Parkes, Cambridge, United Kingdom

Poster exhibition/ Guided poster session

Opening Hours

<i>Poster exhibition</i>	
Thursday, February 20, 2025	10:30 - 18:00
Friday, February 21, 2025	08:00 - 18:00
Saturday, February 22, 2025	09:00 - 13:00

Guided poster session

The guided poster session is on **Friday, February 21, 2025** from **12:40 to 13:40** in the Exhibition Hall (Hall 2.2).

In pairs, poster session chairs will guide groups through the poster exhibition and presenting authors will have the opportunity to share the major findings of their abstracts in 1-2 minutes. In that time, delegates will have the chance to engage with the abstract authors and directly ask any questions.

To join the guided poster session, please choose one of the poster groups listed on the next pages and find the respective poster chairs near the poster exhibition at 12:40 on Friday, February 21, 2025. All poster chairs carry an "ECCO Poster Chair" button and also hold a sign that states the poster group number as well as the scientific category.

Guided poster sessions are chaired by:

(i) Basic Science:

- Group 1** (starts at **P0001**): S. Verstockt, Belgium
G. Bamias, Greece
- Group 2** (starts at **P0029**): R. Dart, United Kingdom
K. Arnauts, Belgium
- Group 3** (starts at **P0057**): E. Filidou, Denmark
G. Doherty, Ireland
- Group 4** (starts at **P0085**): K. Nie, China
A.N. Hegazy, Germany
- Group 5** (starts at **P0113**): H. Sokol, France
G. D'Arcangelo, Italy
- Group 6** (starts at **P0141**): M. Barnhoorn, The Netherlands
J. Clough, United Kingdom
- Group 7** (starts at **P0168**): C. Escudero-Hernández, Germany
O. Brain, United Kingdom
- Group 8** (starts at **P0195**): A. Hart, United Kingdom
B.-J. Ke, Belgium

(ii) Clinical: Diagnosis & Outcome:

- Group 9** (starts at **P0222**): M. Uzzan, France
P. van Rheenen, The Netherlands
- Group 10** (starts at **P0250**): I.A. da Luz Rosa, Portugal
A.R. Bourgonje, United States
- Group 11** (starts at **P0278**): A. Mookhoek, Switzerland
R.M. Feakins, United Kingdom
- Group 12** (starts at **P0306**): A. Centritto, United Kingdom
F. Rieder, United States
- Group 13** (starts at **P0334**): C. Fidalgo, Portugal
L. Fierens, Belgium
- Group 14** (starts at **P0362**): J. van Oostrom, The Netherlands
A. Lightner, United States
- Group 15** (starts at **P0390**): M. Ali, The Netherlands
K. Karmiris, Greece
- Group 16** (starts at **P0418**): P. Kienle, Germany
U. Kopylov, Israel
- Group 17** (starts at **P0445**): A. Hudson, Canada
C. Maaser, Germany
- Group 18** (starts at **P0472**): F. Maccioni, Italy
M. Pierik, The Netherlands
- Group 19** (starts at **P0499**): M. Papatheodoridi, United Kingdom
P. Tozer, United Kingdom

Poster exhibition

- Group 20** (starts at **P0526**): P. Harrow, United Kingdom
A. Trikola, Greece
- Group 21** (starts at **P0553**): A. de Buck van Overstraeten, Canada
N.J.S. Ding, Australia
- (iii) Clinical: Therapy and Observation:**
- Group 22** (starts at **P0580**): M. Bak, The Netherlands
A. Soriano, Italy
- Group 23** (starts at **P0608**): A. Bancil, United Kingdom
G. Pellino, Spain
- Group 24** (starts at **P0636**): M. T. Sharip, United Kingdom
P. Michetti, Switzerland
- Group 25** (starts at **P0664**): V. Pittet, Switzerland
C. Frias Gomes, Portugal
- Group 26** (starts at **P0692**): L. de Ridder, The Netherlands
T. Innocenti, Italy
- Group 27** (starts at **P0720**): A. Bourreille, France
M. Bortlik, Czech Republic
- Group 28** (starts at **P0748**): D. Bettenworth, Germany
A. Moens, Belgium
- Group 29** (starts at **P0776**): D. Lemberg, Australia
D. Noviello, Italy
- Group 30** (starts at **P0804**): K.B. Gecse, The Netherlands
A. Griffiths, Canada
- Group 31** (starts at **P0832**): K. Papamichail, United States
M. Truyens, Belgium
- Group 32** (starts at **P0860**): J. Gisbert, Spain
Z. Istemihan, Turkey
- Group 33** (starts at **P0888**): A. Gojdicova, Slovakia
P. Henderson, United Kingdom
- Group 34** (starts at **P0916**): J.E. De Groof, The Netherlands
H. Peeters, Belgium
- Group 35** (starts at **P0944**): O. Bachmann, Germany
B. Lo, Denmark
- Group 36** (starts at **P0972**): G. Bislenghi, Belgium
R. Brady, United Kingdom
- Group 37** (starts at **P1000**): H. Oliveira Coelho, Portugal
G. Dragoni, Italy
- Group 38** (starts at **P1028**): N. Chanchlani, United Kingdom
T. Kühbacher, Germany
- Group 39** (starts at **P1056**): W. Bemelman, The Netherlands
A. Kellar, United States

- Group 40** (starts at **P1084**): M. Estevinho, Portugal
I. Candel, Canada
- Group 41** (starts at **P1112**): D. de Jong, The Netherlands
C.R. Hedin, Sweden
- Group 42** (starts at **P1140**): F. Rinawi, Israel
B. Shen, United States
- Group 43** (starts at **P1168**): L. Derikx, The Netherlands
M. Toruner, Turkey

(iv) Epidemiology:

- Group 44** (starts at **P1196**): R. Elmahdi, Denmark
J. Limdi, United Kingdom
- Group 45** (starts at **P1220**): J. Burisch, Denmark
P. Riviere, France
- Group 46** (starts at **P1244**): P. L. Lakatos, Canada
J. Wellens, Belgium
- Group 47** (starts at **P1267**): C. Sarbagili Shabat, Israel
E.S. Zagórowicz, Poland

(v) Genetics:

- Group 48** (starts at **P1290**): I. Cleynen, Belgium
M. Parkes, United Kingdom

(vi) Microbiology:

- Group 49** (starts at **P1310**): S. Deleu, Belgium
P. Juillerat, Switzerland
- Group 50** (starts at **P1335**): J. Guedelha Sabino, Belgium
E. Wine, Canada



European
Crohn's and Colitis
Organisation

ECCO IBD APP



The World of ECCO in your pocket

Features and Benefits

- Listen to Audio Podcasts and watch Talking Heads on the go
- Discover the updated IBD Curriculum
- Access ECCO News at any time
- Find more ECCO Initiatives at one glance
- Stay up-to-date in the IBD World
- Explore the ECCO'25 Congress





Educational programme

ECCO aims to promote education and improve the quality of care for IBD patients throughout Europe. Thus, ECCO offers the following educational activities prior to as well as during the 20th Congress of ECCO in Berlin.



6th ECCO Imaging and Endoscopy Workshop in collaboration with ESGAR & IBUS – Group A & B

- Date:** Wednesday, February 19, 2025
Time: 07:30-18:00
Organisation: EduCom in collaboration with ESGAR & IBUS
Target audience: Physicians, Radiologists, Surgeons, Paediatricians
 Other professions are kindly invited to register
Registration: ECCO Membership 2025 required
 Regular/Y-ECCO/IBD Nurse/Affiliate Member or ESGAR Membership
Registration fee: EUR 150,- (half price for Y-ECCO/Affiliate/IBD Nurse Members)
CME accreditation: 8 CME credits

Wednesday, February 19, 2025

Room London 3, CityCube Messe Berlin – Group A
(as of January 23, 2025)

07:30 - 07:40	1A: Welcome & introduction P. Paolantonio, Rome, Italy M. Allocca, Milan, Italy
07:40 - 08:10	Ultrasound and MRI – Introductory lectures
07:40 - 07:55	2A: Entero-MRI – what to look for P. Paolantonio, Rome, Italy
07:55 - 08:10	3A: Intestinal ultrasound – What to look for K. Gecse, Amsterdam, The Netherlands

6th ECCO Imaging and Endoscopy Workshop in collaboration with ESGAR & IBUS

Room London 3, CityCube Messe Berlin – Group A
(as of January 23, 2025)

08:10 - 09:40	Ultrasound and MRI – Hands-on bowel ultrasonography and interactive discussion on Ultrasound MRI workstations – Part 1
08:10 - 09:40	4Aa: Management of suspected IBD N. Krugliak, Chicago, United States J. Rimola, Barcelona, Spain 4Ab: Assessment of Crohn's Disease activity J. Burisch, Copenhagen, Denmark N. Capozzi, Bologna, Italy 4Ac: Intestinal complications of Crohn's Disease C. Maaser, Lüneburg, Germany A. Gupta, London, United Kingdom 4Ad: Post-operative recurrence of Crohn's Disease G. Rogler, Zurich, Switzerland C. Bonifacio, Milan, Italy 4Ae: Perianal Crohn's Disease C. Bezzio, Milan, Italy A. Ramard, Tehran, Iran 4Af: Ulcerative Colitis E. Calabrese, Rome, Italy P. Paolantonio, Rome, Italy
09:40 - 10:10	Ultrasound and MRI – Lectures Part 2
09:40 - 10:10	5A: Tandem Talk: When IUS, when MRI in daily IBD practice? M. Allocca, Milan, Italy F. Maccioni, Rome, Italy
10:10 - 11:40	Ultrasound and MRI – Hands-on bowel ultrasonography and interactive discussion on Ultrasound MRI workstations – Part 2
10:10 - 11:40	6Aa: Management of suspected IBD N. Krugliak, Chicago, United States J. Rimola, Barcelona, Spain 6Ab: Assessment of Crohn's Disease activity J. Burisch, Copenhagen, Denmark N. Capozzi, Bologna, Italy 6Ac: Intestinal complications of Crohn's Disease C. Maaser, Lüneburg, Germany A. Gupta, London, United Kingdom 6Ad: Post-operative recurrence of Crohn's Disease G. Rogler, Zurich, Switzerland C. Bonifacio, Milan, Italy 6Ae: Perianal Crohn's Disease C. Bezzio, Milan, Italy A. Radmard, Tehran, Iran 6Af: Ulcerative Colitis E. Calabrese, Rome, Italy P. Paolantonio, Rome, Italy



*Room London 3, CityCube Messe Berlin – Group A
(as of January 23, 2025)*

11:40 - 12:00 **7A: Closing and farewell**
M. Allocca, Milan, Italy
P. Paolantonio, Rome, Italy

12:00 - 13:30 **Lunch break**

*Room London 2, CityCube Messe Berlin – Group A
(as of January 23, 2025)*

13:30 - 13:45 **8A: Welcome & Introduction**
G. Fiorino, Milan, Italy
U. Kopylov, Ramat Gan, Israel

13:45 - 15:25 **Session 1: Practice endoscopic assessment of inflammation and mucosal healing**
M. Barreiro-de Acosta, Santiago De Compostela, Spain
R. Bisschops, Leuven, Belgium

13:45 - 14:05 **9A: Endoscopy – Key quality indicators for endoscopy in IBD: Why do we need them and what are they?**
A. Walsh, Oxford, United Kingdom

14:05 - 14:30 **10A: Endoscopic scoring system in IBD – colonoscopy assessment in active UC and CD**
M. Barreiro-de Acosta, Santiago De Compostela, Spain

14:30 - 14:50 **11A: Interactive cases: Scoring and reporting in surveillance colonoscopy**
P. Elull, Msida, Malta

14:50 - 15:10 **12A: Indications, assessment and complications of wireless video capsule endoscopy**
U. Kopylov, Ramat Gan, Israel

15:10 - 15:25 **13A: Interactive capsule endoscopy cases in Crohn's Disease**
I. Avni Biron, Petah Tikva, Israel

15:25 - 15:45 **Coffee break**

15:45 - 17:55 **Session 2: Advanced endoscopic techniques and future horizons in Inflammatory Bowel Disease endoscopy**
M. Iacucci, Cork, Ireland
U. Kopylov, Ramat Gan, Israel

15:45 - 16:00 **14A: Endoscopic assessment post-surgical colonic resection**
H. Yanai, Petah Tikva, Israel

16:00 - 16:30 **15A: Managing stricture in IBD: Balloon dilatation, stent or surgery?**
B. Shen, New York, United States

6th ECCO Imaging and Endoscopy Workshop in collaboration with ESGAR & IBUS

Room London 2, CityCube Messe Berlin – Group A (as of January 23, 2025)

16:30 - 16:50	16A: Enhancing characterisation – White light, high definition, dyeless, digital or dye chromoendoscopy M. Iacucci, Cork, Ireland
16:50 - 17:05	17A: Enteroscopy in Crohn's Disease P. Pal, Hyderabad, India
17:05 - 17:35	18A: Characterization and management of advanced dysplasia: EMR, ESD or surgical referral? M. Iacucci, Cork, Ireland
17:35 - 17:55	19A: Artificial Intelligence in UC Endoscopy – The new second reader? R. Bisschops, Leuven, Belgium
17:55 - 18:00	20A: Conclusion M. Barreiro-de Acosta, Santiago De Compostela, Spain

Wednesday, February 19, 2025

Room London 2, CityCube Messe Berlin – Group B (as of January 23, 2025)

07:30 - 07:45	1B: Welcome & introduction G. Fiorino, Milan, Italy U. Kopylov, Ramat Gan, Israel
07:45 - 09:25	Session 1: Practice endoscopic assessment of inflammation and mucosal healing M. Barreiro-de Acosta, Santiago De Compostela, Spain R. Bisschops, Leuven, Belgium
07:45 - 08:05	2B: Endoscopy – Key quality indicators for endoscopy in IBD: Why do we need them and what are they? A. Walsh, Oxford, United Kingdom
08:05 - 08:30	3B: Endoscopic scoring system in IBD – Colonoscopy assessment in active UC and CD M. Barreiro-de Acosta, Santiago De Compostela, Spain
08:30 - 08:50	4B: Interactive cases: Scoring and reporting in surveillance colonoscopy P. Elull, Msida, Malta
08:50 - 09:10	5B: Indications, assessment and complications of wireless video capsule endoscopy U. Kopylov, Ramat Gan, Israel
09:10 - 09:25	6B: Interactive capsule endoscopy cases in Crohn's Disease I. Avni Biron, Petah Tikva, Israel
09:25 - 09:45	Coffee break



*Room London 2, CityCube Messe Berlin – Group B
(as of January 23, 2025)*

09:45 - 11:55	Session 2: Advanced endoscopic techniques and future horizons in Inflammatory Bowel Disease endoscopy M. Iacucci, Cork, Ireland U. Kopylov, Ramat Gan, Israel
09:45 - 10:00	7B: Endoscopic assessment post-surgical colonic resection H. Yanai, Petah Tikva, Israel
10:00 - 10:30	8B: Managing stricture in IBD: Balloon dilatation, stent or surgery? B. Shen, New York, United States
10:30 - 10:50	9B: Enhancing Characterisation – White light, high definition, dyeless, digital or dye chromoendoscopy M. Iacucci, Cork, Ireland
10:50 - 11:05	10B: Enteroscopy in Crohn's Disease P. Pal, Hyderabad, India
11:05 - 11:35	11B: Characterization and management of advanced dysplasia: EMR, ESD or surgical referral? M. Iacucci, Cork, Ireland
11:35 - 11:55	12B: Artificial Intelligence in UC Endoscopy – The new second reader? R. Bisschops, Leuven, Belgium
11:55 - 12:00	13B: Conclusion M. Barreiro-de Acosta, Santiago De Compostela, Spain
12:00 - 13:30	Lunch break

*Room London 3, CityCube Messe Berlin – Group B
(as of January 23, 2025)*

13:30 - 13:40	14B: Welcome & introduction P. Paolantonio, Rome, Italy M. Allocca, Milan, Italy
13:40 - 14:10	Ultrasound and MRI – Introductory lectures
13:40 - 13:55	15B: Entero-MRI – What to look for P. Paolantonio, Rome, Italy
13:55 - 14:10	16B: Intestinal ultrasound – What to look for K. Gece, Amsterdam, The Netherlands

6th ECCO Imaging and Endoscopy Workshop in collaboration with ESGAR & IBUS

Room London 3, CityCube Messe Berlin – Group B
(as of January 23, 2025)

14:10 - 15:40	Ultrasound and MRI – Hands-on bowel ultrasonography and interactive discussion on Ultrasound MRI workstations – Part 1
14:10 - 15:40	17Ba: Management of suspected IBD N. Krugliak Cleveland, Chicago, United States F. Maccioni, Rome, Italy 17Bb: Assessment of Crohn's Disease activity J. Burisch, Copenhagen, Denmark N. Capozzi, Bologna, Italy 17Bc: Intestinal complications of Crohn's Disease K. Gece, Amsterdam, The Netherlands A. Radmard, Tehran, Iran 17Bd: Post-operative recurrence of Crohn's Disease G. Rogler, Zurich, Switzerland C. Bonifacio, Milan, Italy 17Be: Perianal Crohn's Disease C. Bezzio, Milan, Italy M. Amitai, Tel Aviv, Israel 17Bf: Ulcerative Colitis E. Calabrese, Rome, Italy P. Paolantonio, Rome, Italy
15:40 - 16:10	Ultrasound and MRI – lectures Part 2
15:40 - 16:10	18B: Tandem Talk: When IUS, when MRI in daily IBD practice? M. Allocca, Milan, Italy F. Maccioni, Rome, Italy
16:10 - 17:40	Ultrasound and MRI – Hands-on bowel ultrasonography and interactive discussion on Ultrasound MRI workstations – Part 2
16:10 - 17:40	19Ba: Management of suspected IBD N. Krugliak, Chicago, United States F. Maccioni, Rome, Italy 19Bb: Assessment of Crohn's Disease activity J. Burisch, Copenhagen, Denmark N. Capozzi, Bologna, Italy 19Bc: Intestinal complications of Crohn's Disease K. Gece, Amsterdam, The Netherlands A. Radmard, Tehran, Iran 19Bd: Post-operative recurrence of Crohn's Disease G. Rogler, Zurich, Switzerland C. Bonifacio, Milan, Italy 19Be: Perianal Crohn's Disease C. Bezzio, Milan, Italy M. Amitai, Tel Aviv, Israel 19Bf: Ulcerative Colitis E. Calabrese, Rome, Italy P. Paolantonio, Rome, Italy
17:40 - 18:00	20B: Closing and farewell P. Paolantonio, Rome, Italy M. Allocca, Milan, Italy

23rd IBD Intensive Course for Trainees

Date:	Wednesday, February 19, 2025
Time:	08:00-17:20
Organisation:	EduCom
Target audience:	Junior gastroenterologists
Registration:	Upon invitation only ECCO Membership 2025 required Regular/Y-ECCO Member
Registration fee:	N/A
CME accreditation:	7 CME credits

Wednesday, February 19, 2025

Room Paris, CityCube Messe Berlin
(as of January 23, 2025)

08:00 - 08:10	Downloading of the ECCO IBD App
08:10 - 08:15	1: Welcome & Introduction from the course director K. Karmiris, Heraklion, Greece
08:15 - 10:00	Session 1: Epidemiology, pathophysiology and a case-based approach to conventional therapies G. Fiorino, Milan, Italy
08:15 - 08:45	2: IBD: Epidemiology, immunopathogenesis, and their relevance to therapeutics G. Kaplan, Calgary, Canada
08:45 - 09:05	3: 5-ASA compounds K. Karmiris, Heraklion, Greece
09:05 - 09:30	4: Steroids A. Armuzzi, Milan, Italy
09:30 - 10:00	5: Thiopurines, Methotrexate P. Juillerat, Bern, Switzerland
10:00 - 10:20	Coffee break

23rd IBD Intensive Course for Trainees

10:20 - 12:40	Session 2: A case-based approach to advanced therapies and surgery – Tips and tricks F. Magro, Porto, Portugal
10:20 - 10:50	6: Biologics/small molecules in luminal CD G. Doherty, Dublin, Ireland
10:50 - 11:10	7: Biologics and other therapies in complex perianal CD N. Queiroz, Curitiba, Brazil
11:10 - 11:30	8: Post-operative therapies and care in CD M. Ferrante, Leuven, Belgium
11:30 - 12:00	9: Biologics/small molecules in UC T. Kühbacher, Ludwigshafen, Germany
12:00 - 12:20	10: Surgery in IBD: The basics A. Lightner, San Diego, United States
12:20 - 12:40	11: Positioning therapeutic strategies in IBD S. Ben-Horin, Ramat Gan, Israel
12:40 - 14:00	Lunch break
14:00 - 14:30	12: IBD beyond therapies: A comprehensive approach H. Yanai, Petah Tikva, Israel
14:30 - 15:30	Session 3: Round tables – 7 Themes / clinical cases discussion
14:30 - 15:30	13a. Pregnancy C. Hedin, Stockholm, Sweden S. Restellini, Geneva, Switzerland
	13b. Extraintestinal manifestations H. Gordon, Oxford, United Kingdom K. Karmiris, Heraklion, Greece
	13c. When and how to start biologics? P. Juillerat, Bern, Switzerland T. Lobaton, Ghent, Belgium
	13d. Complications associated with anti-TNF therapy A. Sturm, Berlin, Germany M. Törüner, Ankara, Turkey
	13e. Therapeutic drug monitoring N. Queiroz, Curitiba, Brazil B. Ungar, Ramat Gan, Israel
	13f. Exit strategy G. Doherty, Dublin, Ireland M. Ferrante, Leuven, Belgium
	13g. Therapeutic endoscopy in IBD A. Armuzzi, Rome, Italy F. Baert, Roselare, Belgium
15:30 - 15:50	Coffee break

15:50 - 17:10 *Session 3: Round tables – 7 Themes / clinical cases discussion***13a. Pregnancy**

C. Hedin, Stockholm, Sweden

S. Restellini, Geneva, Switzerland

13b. Extraintestinal manifestations

H. Gordon, Oxford, United Kingdom

K. Karmiris, Heraklion, Greece

13c. When and how to start biologics?

P. Juillerat, Bern, Switzerland

T. Lobaton, Ghent, Belgium

13d. Complications associated with anti-TNF therapy**15:50 - 17:10** A. Sturm, Berlin, Germany

M. Törüner, Ankara, Turkey

13e. Therapeutic drug monitoring

N. Queiroz, Curitiba, Brazil

B. Ungar, Ramat Gan, Israel

13f. Exit strategy

G. Doherty, Dublin, Ireland

M. Ferrante, Leuven, Belgium

13g. Therapeutic endoscopy in IBD

A. Armuzzi, Rome, Italy

F. Baert, Roselare, Belgium

17:10 - 17:20 *14: Summary and conclusions*

K. Karmiris, Heraklion, Greece

16th N-ECCO School

Date:	Wednesday, February 19, 2025
Time:	08:30-16:45
Organisation:	N-ECCO
Target audience:	IBD Nurses, Dietitians Other professions are kindly invited to register
Registration:	Upon invitation only ECCO Membership 2025 required IBD Nurse/Affiliate Membership
Registration fee:	N/A
CME accreditation:	N/A

Wednesday, February 19, 2025

Room London 1, CityCube Messe Berlin
(as of January 23, 2025)

08:30 - 08:45	1: Welcome & introduction M. Andersson, Borås, Sweden
08:45 - 12:15	Session 1: Diagnosis and assessment M. Andersson, Borås, Sweden C. Sarbagili Shabat, Holon, Israel
08:45 - 09:30	2: Diagnosis, anatomy and physiology in IBD H. Sokol, Paris, France
09:30 - 10:00	3: Psychosocial implications of living with IBD W. Czuber-Dochan, London, United Kingdom
10:00 - 10:30	4: Nutritional assessment in IBD E. Halmos, Melbourne, Australia
10:30 - 10:45	Coffee break
10:45 - 11:15	5: Surgery in IBD M. Adamina, Winterthur, Switzerland
11:15 - 11:45	6: Medical treatment G. Dragoni, Florence, Italy
11:45 - 12:15	7: Adherence C. Walsh, Donegal, Ireland
12:15 - 13:45	Lunch break

13:45 - 15:15	Session 2: Case studies – Disease management M. Andersson, Borås, Sweden S. Radice, Milan, Italy
13:45 - 14:30	8: UC Management N. Noor, Cambridge, United Kingdom
14:30 - 15:15	9: CD Management V. Solitano, Milan, Italy
15:15 - 15:30	Coffee break
15:30 - 16:30	Session 3: Multidisciplinary management in IBD S. Radice, Milan, Italy V. Svolos, Trikala, Greece
15:30 - 16:00	10: Nutritional management in IBD C. Sarbagili Shabat, Holon, Israel
16:00 - 16:30	11: Nursing roles in IBD management S. Radice, Milan, Italy
16:30 - 16:45	12: Closing remarks M. Andersson, Borås, Sweden

1st Educational Course for Industry Partners

Date:	Wednesday, February 19, 2025
Time:	14:00-18:00
Organisation:	ClinCom
Target audience:	Corporate Members & Non-Corporate Members
Registration:	Online registration
Registration fee:	Non-Corporate Members: EUR 800.– ECCO Corporate Members: EUR 800.–
CME accreditation:	N/A

Wednesday, February 19, 2025

Room New York 3, CityCube Messe Berlin
(as of January 23, 2025)

14:00 - 14:05	1: Welcome M. Chaparro, Madrid, Spain
14:05 - 15:45	Session 1: Insights into IBD Treatment. Bridging the gap between registration studies and clinical practice D. Drobne, Ljubljana, Slovenia
14:05 - 14:25	2: Marrying registration studies with real world evidence J. Kirchengesner, Paris, France
14:25 - 14:45	3: Sequencing and combination treatment R. Atreya, Erlangen, Germany
14:45 - 15:05	4: How ECCO Treatment Guidelines are developed? G. Fiorino, Rome, Italy
15:05 - 15:45	5: Discussion – Knowledge GAPS in IBD treatment Moderator: D. Drobne, Ljubljana, Slovenia R. Atreya, Erlangen, Germany G. Fiorino, Rome, Italy J. Kirchengesner, Paris, France
15:45 - 16:15	Coffee Break
16:15 - 17:55	Session 2: Access to trials and medication T. Kühbacher, Ludwigshafen, Germany
16:15 - 16:35	6: Access to medication in Europe B. Siegmund, Berlin, Germany
16:35 - 16:55	7: Access to medication in Asia T. Kobayashi, Tokyo, Japan
16:55 - 17:15	8: Access to medication in South America F. Steinwurz, Sao Paulo, Brazil
17:15 - 17:55	9: Discussion – Access to medication across the globe T. Kobayashi, Tokyo, Japan B. Siegmund, Berlin, Germany F. Steinwurz, Sao Paulo, Brazil
17:55 - 18:00	10: Closing remarks M. Törüner, Ankara, Turkey

11th Y-ECCO Science Workshop

Date:	Wednesday, February 19, 2025
Time:	12:30-16:30
Organisation:	Y-ECCO
Target audience:	Basic scientists, Physicians, Paediatricians, Surgeons, IBD Nurses
Registration:	Online registration
Registration fee:	EUR 90.-, 50 % reduction for Y-ECCO, Affiliate, IBD Nurse Members
CME accreditation:	3,5 CME credits

Wednesday, February 19, 2025

Room New York 1-2, CityCube Messe Berlin
(as of January 23, 2025)

Remodelling IBD

12:30 - 12:35	1: Introduction B. Verstockt, Leuven, Belgium
12:35 - 13:50	Session 1: Gut in a dish R. Dart, London, United Kingdom J. Neves, London, United Kingdom
12:35 - 13:05	2: Intestinal organoids reveal innate lymphoid cells' functions in health and in IBD J. Neves, London, United Kingdom
13:05 - 13:20	3: Colonic goblet cell dysfunction and gastric intestinal metaplasia in patients with anterior gradient 2 defects and infantile IBD A. Azabdaftari, Berlin, Germany
13:20 - 13:35	4: Optimized inflammatory and ER stress-induced phenotypes in differentiated intestinal organoids for modelling IBD L. Giorio, Leuven, Belgium
13:35 - 13:50	5: Study of the implicatoin oft he epithelium in the development and progression of fibrosis in Ulcerative Colitis M. Stepniak, Liège, Belgium
13:50 - 14:15	Meet the speakers break

14:15 - 15:30	Session 2: Unravelling bowel damage G. Dragoni, Florence, Italy F. Rieder, Cleveland, United States
14:15 - 14:45	6: Mechanisms and clinical trial endpoints for intestinal fibrosis F. Rieder, Cleveland, United States
14:45 - 15:00	7: JAK inhibition to target fibroblasts and IBD-related fibrosis J. Su, Leiden, The Netherlands
15:00 - 15:15	8: Measurement of collagen concentration throughout the intestinal layers using Deep Learning: Implications in Inflammatory Bowel Diseases (IBD) E. Tsounis, Patras, Greece
15:15 - 15:30	9: Multiomic Analysis Reveals Three Distinct subtypes within Perianal Crohn's Disease, Independent of Concomitant Proctitis S. Abdurahiman, Leuven, Belgium
15:30 - 16:25	Session 3: Perianal Crohn's Disease N. Powell, London, United Kingdom V. Solitano, Milan, Italy
15:30 - 15:55	10: The pathophysiology of perianal fistulizing Crohn's Disease N. Powell, London, United Kingdom
15:55 - 16:10	11: Ablating perianal fistulizing Crohn's Disease through genetically engineered patient specific induced pluripotent stem cells (iPSC)-derived stromal cells I. Molendijk, Rotterdam, The Netherlands
16:10 - 16:25	12: Immune-epithelial crosstalk boosting intestinal repair in Ulcerative Colitis A. Hausmann, Copenhagen, Denmark
16:25 - 16:30	13: Closing remarks B. Verstockt, Leuven, Belgium



12th ECCO Ultrasound Workshop – Advanced in collaboration with ESGAR & IBUS



international bowel
ULTRASOUND GROUP



Date:	Thursday, February 20, 2025
Time:	07:45-11:45
Organisation:	EduCom in collaboration with ESGAR & IBUS
Target audience:	Physicians, Radiologists, Surgeons, Paediatricians
Registration:	ECCO Membership 2025 required Regular/Y-ECCO/IBD Nurse/Affiliate Member or ESGAR membership
Registration fee:	EUR 100.–, 50 % reduction for Y-ECCO, Affiliate, IBD Nurse Members
CME accreditation:	3,5 CME credits

Thursday, February 20, 2025

Room London 2, CityCube Messe Berlin
(as of January 23, 2025)

07:45 - 07:50	1: Welcome & introduction M. Allocca, Milan, Italy P. Paolantonio, Rome, Italy
07:50 - 09:35	Session 1: Assessment of IBD C. Maaser, Lüneburg, Germany P. Paolantonio, Rome, Italy
07:50 - 08:05	2: Ultrasound activity scores in Crohn's Disease G. Dragoni, Florence, Italy
08:05 - 08:25	3: Interactive video presentation 1 – Monitoring and response to treatment G. Dragoni, Florence, Italy
08:25 - 09:00	4: Intestinal ultrasound for IBD trials M. Allocca, Milan, Italy
09:00 - 09:15	5: Ultrasound activity scores in Ulcerative Colitis B. Verstockt, Leuven, Belgium
09:15 - 09:35	6: Interactive video presentation 2 – Monitoring and response to treatment B. Verstockt, Leuven, Belgium
09:35 - 10:00	Coffee break

12th ECCO Ultrasound Workshop – Adv. in collaboration with ESGAR & IBUS

10:00 - 11:30	Session 2: IUS special situations M. Allocca, Milan, Italy P. Paolantonio, Rome, Italy
10:00 - 10:15	7: IUS assessment of strictures K. Gecse, Amsterdam, The Netherlands
10:15 - 10:30	8: Interactive video presentation 3 – Diagnosis and characterization K. Gecse, Amsterdam, The Netherlands
10:30 - 10:55	9: IUS assessment of abscesses C. Bezzio, Milan, Italy
10:55 - 11:10	10: Interactive video presentation 4 – Diagnosis and characterization C. Bezzio, Milan, Italy
11:10 - 11:30	11: Ultrasound and future development C. Maaser, Lüneburg, Germany
11:30 - 11:45	12: Post course test: Summary and closing remarks M. Allocca, Milan, Italy P. Paolantonio, Rome, Italy

12th P-ECCO Educational Course

Date:	Thursday, February 20, 2025
Time:	09:00-11:00
Organisation:	P-ECCO
Target audience:	Paediatricians, Physicians, Surgeons
Registration:	ECCO Membership 2025 required Regular/Y-ECCO/IBD Nurse/Affiliate Membership
CME accreditation:	2 CME credits

Thursday, February 20, 2025

Room London 3, CityCube Messe Berlin

(as of January 23, 2025)

09:00 - 11:00	<i>The multidisciplinary journey of the paediatric patient with complex IBD</i> D. Shouval, Petah Tiqva, Israel
09:00 - 09:05	1: Introduction D. Shouval, Petah Tiqva, Israel
09:05 - 09:25	2: What do you do with the gut in UC-PSC? K.-L. Kolho, Helsinki, Finland
09:25 - 09:50	3: Tandem Talk: Medical and surgical management of perianal Crohn's Disease C. Buskens, Amsterdam, The Netherlands S. Hussey, Dublin, Ireland
09:50 - 10:10	4: Risk of infection in paediatric IBD patients on immunosuppressant drugs F. Rinawi, Afula, Israel
10:10 - 10:40	5: Tandem Talk: The VEOIBD patient: diagnosis, nutritional management and medical intervention I. Hojsak, Zagreb, Croatia D. Kotlarz, Munich, Germany D. Shouval, Petah Tikva, Israel
10:40 - 11:00	6: The medical-refractory IBD patient: what to do when everything fails? An adult perspective S. Vermeire, Leuven, Belgium

13th SciCom Workshop: Diet in IBD

Date:	Thursday, February 20, 2025
Time:	08:45-11:45
Organisation:	SciCom
Target audience:	Basic scientists and interested clinicians
Registration:	ECCO Membership 2025 required Regular/Y-ECCO Member
Registration fee:	EUR 90.–, 50 % reduction for Y-ECCO, Affiliate, IBD Nurse Members
CME accreditation:	2,5 CME credits

Thursday, February 20, 2025

Room New York 3, CityCube Messe Berlin
(as of January 23, 2025)

08:45 - 10:05	<i>Session 1: Role of diet in pathogenesis and assessment of nutritional status</i> B. Ungar, Ramat Gan, Israel J. Vanderstappen, Leuven, Belgium
08:45 - 08:50	<i>1: Welcome & Introduction</i> I. Cleynen, Leuven, Belgium
08:50 - 09:28	<i>2: Tandem Talk: Diet – Microbiome interactions and IBD</i> A. Griffiths, Toronto, Canada H. Sokol, Paris, France
09:28 - 10:05	<i>3: Tandem Talk: Assessment of nutrition status in adult and children (addressing refeeding syndrome)</i> M. Lomer, London, United Kingdom C. Sarbagili Shabat, Holon, Israel
10:05 - 10:25	<i>Coffee break</i>
10:25 - 11:45	<i>Session 2: Role of diet in management of disease</i> R. Hansen, Dundee, United Kingdom P. Myrelid, Linköping, Sweden
10:25 - 10:50	<i>4: How to perform studies on diets – best practice, case examples</i> E. Halmos, Melbourne, Australia
10:50 - 11:15	<i>5: Diet in the management of CD flare</i> E. Wine, Edmonton, Canada
11:15 - 11:40	<i>6: Diet in the management of IBD maintenance</i> H. Gordon, Oxford, United Kingdom
11:40 - 11:45	<i>7: Closing remarks</i> V. Svolos, Trikala, Greece

19th N-ECCO Network Meeting

Date:	Thursday, February 20, 2025
Time:	09:00-17:00
Organisation:	N-ECCO
Target audience:	IBD Nurses – advanced level
Registration:	ECCO Membership 2025 required IBD Nurse Membership
Registration fee:	EUR 35.–
CME accreditation:	N/A

Thursday, February 20, 2025

Room New York 1-2, CityCube Messe Berlin
(as of January 23, 2025)

09:00 - 09:10	1: Welcome & introduction S. Radice, Milan, Italy
09:10 - 10:30	Session 1: Changing the horizon of medication P. Hartmann, Minden, Germany S. Radice, Milan, Italy
09:10 - 09:30	2: Update on medical treatment – drugs or diet? A. Hart, London, United Kingdom
09:30 - 09:50	3: Nurse and prescribing of medication – changing of the landscape (why it is useful and how nurses got there) M. de Jong, Amsterdam, The Netherlands
09:50 - 10:10	4: Medication adherence K. King, London, United Kingdom
10:10 - 10:30	5: When is the right time to stop therapy? T. Kühbacher, Ludwigshafen, Germany
10:30 - 11:00	Coffee break
11:00 - 12:30	Session 2: Innovations in research and practice C. Walsh, Donegal, Ireland A. Rivera Sequeiros, Sevilla, Spain
11:00 - 11:30	6: 4 pillars of advance practice W. Czuber-Dochan, London, United Kingdom
11:30 - 11:45	7: N01: Sexuality and IBD. Does it need to be talked about in IBD centres? Results of an anonymous survey at IBD-Patients, -Nurses und -Physicians (MD) in Germany (IBD-INTIM!) P. Hartmann, Minden, Germany
11:45 - 12:00	8: N02: Supporting psychosocial and emotional well-being and building resilience in family members of people with IBD: RCT feasibility and acceptability study P. Thapwong, London, United Kingdom

12:00 - 12:15	9: N03: The impact of IBD on sexual health: A gender-based cross-sectional comparison with a non-IBD population Z. Pérez Martínez, Terrasa, Spain
12:15 - 12:30	10: N04: Optimizing patient-reported outcome measurement in an IBD care pathway: Results of the PROMOTION study N. Lembrechts, Bonheidenn, Belgium
12:30 - 14:00 Lunch break	
14:00 - 14:45	Session 3: New frontier of telemedicine M. de Jong, Amsterdam, The Netherlands C. Walsh, Donegal, Ireland
14:00 - 14:20	11: Community care (how do we follow up patients – innovative care) M. Andersson, Borås, Sweden M. de Jong, Amsterdam, The Netherlands S. Radice, Milan, Italy
14:20 - 14:45	12: Use of AI in follow up care How to bring AI care into IBD A. Rivera Sequeiros, Sevilla, Spain
14:45 - 15:15 Coffee break	
15:15 - 16:30	Session 4: Breaking taboos: Bringing sexuality and fertility into clinical consultations M. de Jong, Amsterdam, The Netherlands M. Estevinho, Vila Nova de Gaia, Portugal
15:15 - 15:40	13: Assessing patient needs in sexuality and fertility P. Hartmann, Minden, Germany
15:40 - 16:05	14: Sex and body image talk P. Tozer, London, United Kingdom
16:05 - 16:50	15: Panel discussion: P. Hartmann, Minden, Germany M. Petitmangin, Berlin, Germany S. Radice, Milan, Italy P. Tozer, London, United Kingdom C. Walsh, Donegal, Ireland
16:50 - 17:00	16: Closing remarks S. Radice, Milan, Italy



4th ECCO Postgraduate Course in IBD

Date: Thursday, February 20, 2025
Time: 07:30-12:05
Organisation: EduCom
Recommended for: Experienced Gastroenterologists with interest in IBD
Other professions are kindly invited to register
Registration: ECCO Membership 2025 required
CME accreditation: 4 CME credits

Thursday, February 20, 2025

Room A1, CityCube Messe Berlin
(as of January 23, 2025)

07:30 - 07:40	1: Introduction K. Karmiris, Heraklion, Greece F. Magro, Porto, Portugal
07:40 - 09:45	Session 1: Prepare yourself with IBD Experts U. Kopylov, Ramat Gan, Israel F. Magro, Porto, Portugal
07:40 - 08:00	2: Which are the "realistic?" objectives in IBD in 2025? S. Vermeire, Leuven, Belgium
08:00 - 08:30	3: How do I select biologics or small molecules in CD? A. Dignass, Frankfurt, Germany
08:30 - 09:00	4: How do I select biologics or small molecules in UC? J. Lindsay, London, United Kingdom
09:00 - 09:25	5: Update on the management of post-operative CD H. Yanai, Petah Tikva, Israel
09:25 - 09:45	6: How do I monitor IBD patients? A. Armuzzi, Milan, Italy
09:45 - 10:00	Coffee break

10:00 - 12:00	Session 2: Case-based discussion with IBD Experts K. Karmiris, Heraklion, Greece M. Barreiro-de Acosta, Santiago De Compostela, Spain
10:00 - 11:00	7: CD cases presentation: a: Multi-refractory CD during pregnancy b: Medical management (including pregnancy) c: Panel discussion – Q&A and conclusion Speaker: N. Queiroz, Curitiba, Brazil Moderator: K. Karmiris, Heraklion, Greece Panelists: E. Louis, Liège, Belgium U. Kopylov, Ramat Gan, Israel
11:00 - 12:00	8: UC cases presentation: a: Steroid-dependent UC b: Medical treatment/Sequencing drugs c: Panel discussion – Q&A and conclusion Speaker: I. Rodriguez-Lago, Bilbao, Spain Moderator: M. Barreiro-de Acosta, Santiago De Compostela, Spain Panelists: G. Doherty, Dublin, Ireland P. Juillerat, Bern, Switzerland
12:00 - 12:05	9: Conclusion and remarks M. Barreiro-de Acosta, Santiago De Compostela, Spain U. Kopylov, Ramat Gan, Israel



14th S-ECCO IBD Masterclass in collaboration with ESCP

Date:	Thursday, February 20, 2025
Time:	08:00-17:00
Organisation:	S-ECCO in collaboration with ESCP
Target audience:	Surgeons, Physicians, IBD Nurses
Registration:	ECCO Membership 2025 required Regular/Y-ECCO/IBD Nurse Membership
Registration fee:	EUR 150.-, 50 % reduction for Y-ECCO, Affiliate, IBD Nurse Members
CME accreditation:	6 CME credits



Thursday, February 20, 2025

Room A5, CityCube Messe Berlin

(as of January 23, 2025)

08:00 - 08:10	1: Welcome O. Faiz, Harrow, United Kingdom
08:10 - 10:05	Session 1: Challenges in IBD surgery A. El-Hussuna, Aalborg, Denmark S. Sebastian, Hull, United Kingdom
08:10 - 08:55	Challenges in different geographical regions
08:10 - 08:25	2: Medical aspects N. Queiroz, Curitiba, Brazil
08:25 - 08:40	3. Procedure / Technological aspects A. Roslani, Kuala Lumpur, Malaysia
08:40 - 08:50	4. Discussion
08:50 - 09:35	Appendectomy in UC: Debate W. Bemelman, Amsterdam, The Netherlands A. Lightner, San Diego, United States
08:50 - 09:05	5: In favour of appendectomy T. Pinkney, Birmingham, United Kingdom
09:05 - 09:20	6: Against appendectomy A. Christensen, Odense, Denmark
09:20 - 09:35	7: Discussion

14th S-ECCO IBD Masterclass in collaboration with ESCP

09:35 - 10:05	Session 2: Perioperative optimisation P. Kienle, Mannheim, Germany G. Bislenghi, Leuven, Belgium
09:35 - 09:50	8: Preoperative considerations C. Nordenvall, Stockholm, Sweden
09:50 - 10:05	9: Postoperative considerations H. Yanai, Petah Tikva, Israel
10:05 - 10:35	Coffee break
10:35 - 11:30	Session 3: IBD Global updates W. Bemelman, Amsterdam, The Netherlands C. Nordenvall, Stockholm, Sweden
10:35 - 10:50	10: IBD surgery in Low - and Middle - Income Countries N. Avellaneda, Buenos Aires, Argentina
10:50 - 11:00	11: Efficacy of appendectomy in inducing remission in moderate-to-severe Ulcerative Colitis: Preliminary one year results of a multicentre prospective cohort study (COSTA) E. Visser, Amsterdam, The Netherlands
11:00 - 11:10	12: International differences in pre-operative characteristics and postoperative management in patients with Crohn's Disease following ileocolic resection: A report from the IMPACT consortium M. Bak, Rotterdam, The Netherlands
11:10 - 11:20	13: TRIOCOL C. Nordenvall, Stockholm, Sweden
11:20 - 11:30	14: Bicentric Data on Colectomies G. Bislenghi, Leuven, Belgium
11:30 - 13:00	Lunch break
13:00 - 15:15	Session 4: Colectomy in IBD dysplasia O. Faiz, Harrow, United Kingdom C. Nordenvall, Stockholm, Sweden
13:00 - 13:15	15: Endoscopic resection A. Hart, Harrow, United Kingdom
13:15 - 13:30	16: Extent of resection P. Kienle, Mannheim, Germany
13:30 - 13:55	17: Presentation of cases for discussion A. Hart, Harrow, United Kingdom P. Kienle, Mannheim, Germany
13:55 - 14:35	Surgical technique session: Pouch surgery
13:55 - 14:10	18: Ileoanal anastomosis A. Spinelli, Rozzano, Italy
14:10 - 14:25	19: Continent pouches P. Myrelid, Linköping, Sweden
14:25 - 14:35	20: Discussion

14:35 - 15:15 <i>Surgical technique session: Perianal surgery</i>	
14:35 - 14:50	21: Seton vs. definitive repair C. Buskens, Amsterdam, The Netherlands
14:50 - 15:05	22: LIFT vs. reconstruction A. Lightner, San Diego, United States
15:05 - 15:15	23: Discussion
15:15 - 15:45 <i>Coffee break</i>	
Session 5: On the rim of the future	
15:45 - 16:15	P. Kienle, Mannheim, Germany A. de Buck van Overstraeten, Toronto, Canada
15:45-16:00	24: AI in the theatre A. El-Hussuna, Aalborg, Denmark
16:00-16:15	25: Innovation of stoma care R. Brady, Newcastle, United Kingdom
Session 6: Consultants' corner on challenging cases	
16:15 - 16:45	W. Bemelman, Amsterdam, The Netherlands A. D'Hoore, Leuven, Belgium A. El-Hussuna, Aalborg, Denmark P. Myrelid, Linköping, Sweden N. Queiroz, Curitiba, Brazil
16:15 - 16:30	26: Challenging case 1
16:30 - 16:45	27: Challenging case 2
16:45 - 17:00	28: Closing remarks A. El-Hussuna, Aalborg, Denmark

6th School for Clinical Trialists

Date:	Wednesday, February 19, 2025
Time:	08:00-11:30
Organisation:	ClinCom
Recommended for:	Clinical trial coordinators, IBD Nurses and Allied health professionals
Registration:	ECCO Membership 2025 required Regular/Y-ECCO Member
Registration fee:	EUR 60.–, online registration
CME accreditation:	2,5 CME credits

Wednesday, February 19, 2025

Room New York 3, CityCube Messe Berlin
(as of January 23, 2025)

How to be successful as a trialist: from A to Z

08:00 - 08:10	1: Welcome & Introduction M. Chaparro, Madrid, Spain
08:10 - 09:30	Session 1: The pathway for a trialist M. Chaparro, Madrid, Spain
08:10 - 08:30	2: How to start as a trialist: First steps in a great adventure J. Kirchgesner, Paris, France
08:30 - 08:50	3: How to organize an IBD research unit from scratch S. Vermeire, Leuven, Belgium
08:50 - 09:10	4: How to create a global consortium: To the infinity and beyond A. Hart, Harrow, United Kingdom
09:10 - 09:30	5: Discussion All together
09:30 - 10:00	Coffee break
10:00 - 11:20	Session 2: All you need to know about trials J. Kirchgesner, Paris, France
10:00 - 10:20	6: Revisiting clinical trials design N. Noor, Cambridge, United Kingdom
10:20 - 10:40	7: Facing regulatory issues across countries K. Gecse, Amsterdam, The Netherlands
10:40 - 11:00	8: The full story: From database architecture to the last patient out E. Louis, Liège, Belgium
11:00 - 11:20	9: Every patient counts: Underrepresented populations in research S. Sebastian, Hull, United Kingdom
11:20 - 11:30	10: Summary & closing remarks J. Kirchgesner, Paris, France

6th ECCO-AOCC Global Forum

Date: Thursday, February 20, 2024
Time: 08:50-11:40
Organisation: ECCO Governing Board
Recommended for: Physicians, Surgeons
Registration: Online registration

Thursday, February 20, 2025

Room Paris, CityCube Messe Berlin
(as of January 23, 2025)

08:50 - 09:00	1: Welcome & Introduction B. Siegmund, Berlin, Germany
09:00 - 10:00	Session 1: Global IBD development and challenges ECCO Chair: R. Banerjee, Hyderabad, India AOCC Chair: K. Matsuoka, Chiba, Japan
09:00 - 09:30	2: Challenges for IBD care R. Banerjee, Hyderabad, India
09:30 - 10:00	3: Diagnostic challenges – ESGAR imaging speaker A. Radmard, Tehran, Iran
10:00 - 10:30	Coffee Break
10:30 - 11:40	Session 2: The future of diagnosing IBD ECCO Chair: S. Sebastian, Hull, United Kingdom AOCC Chair: E.S. Kim, Daegu, Korea
10:30 - 11:00	4: AI – the future of diagnosing and scoring IBD? E.S. Kim, Daegu, Korea
11:00 - 11:30	5: Ultrasound – complementary diagnostic tool? E. Calabrese, Rome, Italy
11:30 - 11:40	6: Closing remarks F. Magro, Porto, Portugal

10th H-ECCO IBD Masterclass

Date:	Thursday and Friday, February 20-21, 2025
Time:	Thursday, February 20: 13:30-17:15 Friday, February 21: 08:00-12:00
Organisation:	H-ECCO, endorsed by ESP
Target audience:	Histopathologists, Clinicians
Registration:	ECCO Membership 2025 required Regular/Y-ECCO/IBD Nurse/ Affiliate Membership
Registration fee:	EUR 90.– (incl. VAT), 50 % reduction for Y-ECCO, Affiliate & IBD Nurse Members
CME accreditation:	6,5 CME credits



European
Society of
Pathology

Thursday, February 20, 2025

Room New York 3, CityCube Messe Berlin

(as of January 23, 2025)

13:30 - 13:35	1: Welcome A. Mookhoek, Bern, Switzerland
13:35 - 15:15	Session 1: Basics of IBD H. Oliveira Coelho, Lisboa, Portugal M. Törüner, Ankara, Turkey
13:35 - 13:55	2: Tandem talk: Collaboration of endoscopist and histopathologist in the diagnosis of IBD M. Törüner, Ankara, Turkey A. Ensari, Ankara, Turkey
13:55 - 14:15	3: Definitions in histopathology reporting R. Feakins, London, United Kingdom
14:15 - 14:30	4: Classical patterns of UC A. Mookhoek, Bern, Switzerland
14:30 - 14:50	5: Classical patterns of CD H. Oliveira Coelho, Lisboa, Portugal
14:50 - 15:15	6: Non-classical patterns of IBD P. Baldin, Woluwe-Saint-Lambert, Belgium
15:15 - 15:45	Coffee break
15:45 - 17:15	Session 2: Mimics P. Baldin, Woluwe-Saint-Lambert, Belgium J. Burisch, Hvidovre, Denmark
15:45 - 16:05	7: Clinical mimics of IBD J. Burisch, Hvidovre, Denmark
16:05 - 16:25	8: Drug induced colitis R. Feakins, London, United Kingdom
16:25 - 16:40	9: Infections A. Driessen, Edegem, Belgium

16:40 - 16:55	10: Diversion and diverticular colitis H. Oliveira Coelho, Lisboa, Portugal
16:55 - 17:15	11: Rare mimics R. Feakins, London, United Kingdom

Friday, February 21, 2025

Room New York 3, CityCube Messe Berlin
(as of January 23, 2025)

Session 3: Advanced	
08:00 - 09:45	A. Ensari, Ankara, Turkey F. Magro, Porto, Portugal
08:00 - 08:30	12: Tandem Talk: Disease activity assessment with endoscopic and histologic scores F. Magro, Porto, Portugal A. Mookhoek, Bern, Switzerland
08:30 - 08:50	13: Histological scoring systems in clinical practice P. Borralho Nunes, Lisbon, Portugal
08:50 - 09:05	14: IBD and primary immunodeficiencies A. Ensari, Ankara, Turkey
09:05 - 09:25	15: IBD in children P. Borralho Nunes, Lisbon, Portugal
09:25 - 09:45	16: Dysplasia A. Driessen, Edegem, Belgium
09:45 - 10:15	Coffee break
Session 4: Future of IBD	
10:15 - 11:55	A. Mookhoek, Bern, Switzerland I. Nagtegaal, Nijmegen, The Netherlands
10:15 - 10:40	17: Biomarkers H. Oliveira Coelho, Lisboa, Portugal
10:40 - 10:55	18: Hot topics in IBD A. Driessen, Edegem, Belgium
10:55 - 11:10	19: Synoptic reporting I. Nagtegaal, Nijmegen, The Netherlands
11:10 - 11:25	20: Hyperplex immunofluorescence A. Mookhoek, Bern, Switzerland
11:25 - 11:40	21: Artificial Intelligence-based prediction of Nancy Grade activity using digital pathology in Ulcerative Colitis patients J. E. Kim, Seoul, Republic of Korea
11:40 - 11:55	22: Updates in AI A. Ensari, Ankara, Turkey
11:55 - 12:00	24: Closing remarks A. Mookhoek, Bern, Switzerland

10th D-ECCO Workshop

Date:	Friday, February 21, 2025
Time:	08:15-12:25
Organisation:	D-ECCO
Target audience:	Dietitians, IBD Nurses, Physicians
Registration:	ECCO Membership 2025 required Regular/Y-ECCO/IBD Nurse/Affiliate Member
Registration fee:	EUR 60.–
CME accreditation:	3,5 CME credits

Friday, February 21, 2025

Room New York 1-2, CityCube Messe Berlin
(as of January 23, 2025)

08:15 - 08:20	1: Welcome C. Sarbagili Shabat, Holon, Israel
08:20 - 09:30	Session 1: Food science: Diet, gut and microbes V. Svolos, Trikala, Greece J. Vanderstappen, Leuven, Belgium
08:20 - 08:40	2: Diet and FMT interaction C. Sarbagili Shabat, Holon, Israel
08:40 - 09:00	3: To fibre or not to fibre C. Yao, Melbourne, Australia
09:00 - 09:20	4: Personalised nutrition in IBD K. Gkikas, Glasgow, United Kingdom
09:20 - 09:30	5: The effects of high and low emulsifier diets in active Crohn's Disease: A pilot double-blinded randomised feeding trial J. Fitzpatrick, Melbourne, Australia
09:30 - 09:50	Coffee break
09:50 - 10:50	Session 2: Dietary management in IBD: Novel approaches A. Sandall, London, United Kingdom C. Sarbagili Shabat, Holon, Israel
09:50 - 10:10	6: Ultra-processed food – barriers to clinical practice E. Halmos, Melbourne, Australia
10:10 - 10:30	7: Applications of partial enteral nutrition in CD V. Svolos, Trikala, Greece
10:30 - 10:50	8: Tandem talk: Acute severe UC J. Vanderstappen, Leuven, Belgium B. Verstockt, Leuven, Belgium
10:50 - 11:10	Coffee break

11:10 - 12:20	Session 3: Interactive session: Diet throughout the lifespan E. Halmos, Melbourne, Australia V. Svolos, Trikala, Greece
11:10 - 11:20	9: Fecal calprotectin response to Tasty&Healthy dietary intervention in asymptomatic children and young adults with biologically active Crohn's Disease: Results of the "TASTI-E" randomized controlled triale L. Plotkin, Netanya, Israel
11:20 - 11:40	10: Tandem case presentation: Paediatrics/child growth in IBD I. Hojsak, Zagreb, Croatia S. Sila, Zagreb, Croatia
11:40- 12:00	11: Nutritional considerations in elderly IBD A. Sandall, London, United Kingdom
12:00- 12:20	12: Panel case discussion – dietary therapy across the lifespan I. Hojsak, Zagreb, Croatia M. Samaan, London, United Kingdom A. Sandall, London, United Kingdom S. Sila, Zagreb, Croatia
12:20 - 12:25	13: Closing remarks C. Sarbagili Shabat, Holon, Israel

EFCCA Conference

Date: Thursday, February 20, 2025
Time: 08:15-10:30
Organisation: EFCCA
Registration: EFCCA

Thursday, February 20, 2025

Room A4, CityCube Messe Berlin
(as of January 23, 2025)

What do IBD patients find important in their treatment? Results from a global Patient Preference survey

08:15 - 08:30	<i>Opening remarks</i> S. Leone, EFCCA Chairman <i>Welcome</i> B. Siegmund, ECCO President, Charité – University Hospital Berlin
08:30 - 08:45	<i>Setting the scene</i> B. Verstockt, Leuven, Belgium
08:45 - 09:00	<i>“Patient Preference Journey”</i> M. S. De Rocchis, EFCCA EU Project Officer
09:00 - 09:30	<i>Presentation of Results of the Patient Preference survey</i> E. Schoefs, Leuven, Belgium
09:30 - 10:00	<i>Panel discussion: Patients under the spotlight</i> Moderator: L. Avedano, EFCCA CEO Panelists: R. Saldaña – DIVA: Patients’ opinions matter V. Vakouftsi – Youngsters’ perspective
10:00 - 10:10	<i>The IBD Nurses’ perspective</i> C. Walsh, N-ECCO Committee
10:10 - 10:30	<i>Questions and answers</i> <i>Closing remarks</i>

Industry sponsored Satellite Symposia

Industry sponsored Satellite Symposia organised by pharmaceutical companies are open to all congress participants. The programmes of symposia are not affiliated with ECCO and sponsors hold responsibility for the content of their respective programmes.

Industry sponsored Satellite Symposia – Scientific programme

Thursday, February 20, 2025


Johnson & Johnson	Satellite Symposium 1a Organiser: Johnson & Johnson Meeting room: Plenary Hall/Hall B
11:00 - 12:00	Expanding the universe in IBD: Going beyond in Crohn's Disease I. Dotan, Petah Tikva, Israel S. Danese, Milan, Italy
11:00 - 11:04	Welcome and introduction S. Danese, Milan, Italy
11:04 - 11:14	The next frontier in IBD: The journey to IL-23 targeted therapy I. Dotan, Petah Tikva, Israel
11:14 - 11:18	Looking among the stars: CD64 – expressing myeloid cells in IBD J. Torres, Loures, Portugal
11:18 - 11:36	Overcoming gravity in Crohn's Disease: Achieving clinical outcomes for patients M. Fumery, Amiens, France J. Torres, Loures, Portugal Moderator: I. Dotan, Petah Tikva, Israel
11:36 - 11:46	Exploring new galaxies in Crohn's Disease: Achieving high-bar objective endpoints S. Danese, Milan, Italy
11:46 - 11:56	Creating the big bang in Crohn's Disease: Combining the physicians and patient's perspectives S. Danese, Milan, Italy M. Fumery, Amiens, France J. Torres, Loures, Portugal Moderator: I. Dotan, Petah Tikva, Israel
11:56 - 12:00	Summary and close I. Dotan, Petah Tikva, Israel

Industry Sessions

	Satellite Symposium 1b Organiser: AbbVie Meeting room: Parallel Hall/A7
11:00 - 12:00	Get it right from the start in Crohn's Disease J. Lindsay, London, United Kingdom
11:00 - 11:05	Welcome and introduction J. Lindsay, London, United Kingdom
11:05 - 11:20	Choosing the right strategy for disease control P. Bossuyt, Bonheiden, Belgium
11:20 - 11:36	Spotlight on IL-23 and JAK inhibitors in CD S. Zeissig, Greifswald, Germany
11:36 - 11:49	A spectrum of evidence: From clinical trials to the real world J. Lindsay, London, United Kingdom
11:49 - 11:55	Faculty Q&A All faculty led by J. Lindsay, London, United Kingdom
11:55 - 12:00	Summary and close J. Lindsay, London, United Kingdom

	Satellite Symposium 1c Organiser: Takeda Meeting room: A8
11:00 - 12:00	Early vs personalized treatment for Crohn's Disease: Is there more than one path to disease control? G. D'Haens, Amsterdam, The Netherlands
11:00 - 11:05	Welcome and introduction G. D'Haens, Amsterdam, The Netherlands
11:05 - 11:20	Treat early, treat better: The case for early intervention S. Ben-Horin, Tel-Aviv, Israel
11:20 - 11:35	Right treatment, right time: The case for personalized therapy P. Dulai, Chicago, United States
11:35 - 11:50	Moderated Q&A and rebuttals All faculty
11:50 - 11:55	Closing statements S. Ben-Horin, Tel-Aviv, Israel P. Dulai, Chicago, United States
11:55 - 12:00	Summary and close G. D'Haens, Amsterdam, The Netherlands

 <small>A MEDICINE COMPANY</small>	Satellite Symposium 1d Organiser: Eli Lilly & Company Meeting room: A4
11:00 - 12:00	<i>Moving into the future: Comprehensive management of Crohn's Disease with IL-23p19 inhibition</i> S. Schreiber, Kiel, Germany S. Vavricka, Zürich, Switzerland
11:00 - 11:05	<i>Welcome and introductions</i> S. Schreiber, Kiel, Germany
11:05 - 11:20	<i>Comprehensive management of CD</i> S. Schreiber, Kiel, Germany
11:20 - 11:40	<i>Efficacy of IL-23p19 inhibition in CD</i> S. Vavricka, Zürich, Switzerland
11:40 - 11:50	<i>Safety of targeting IL-23p19 in CD</i> S. Schreiber, Kiel, Germany
11:50 - 12:00	<i>Summary and Q&A</i> S. Schreiber, Kiel, Germany S. Vavricka, Zürich, Switzerland

	Satellite Symposium 1e Organiser: Pfizer Meeting room: Helsinki 1
11:00 - 12:00	<i>Expanding the conversation on S1P receptor modulators and JAK inhibitors in UC</i> I. Blumenstein, Frankfurt, Germany
11:00 - 11:05	<i>Welcome and overview</i> I. Blumenstein, Frankfurt, Germany
11:05 - 11:35	<i>Examining advanced oral therapies in UC</i> I. Blumenstein, Frankfurt, Germany K. Gecse, Amsterdam, The Netherlands R. Panaccione, Calgary, Canada
11:35 - 11:55	<i>Discussing the options: patient management in UC</i> I. Blumenstein, Frankfurt, Germany K. Gecse, Amsterdam, The Netherlands R. Panaccione, Calgary, Canada
11:55 - 12:00	<i>Summary</i> I. Blumenstein, Frankfurt, Germany

FERRING

PHARMACEUTICALS

Helping people live better lives

Come and visit our Ferring Pharmaceuticals booth in **Hall 4.2b** to:

- Meet our experts in IBD
- Discover the newly published **OPTIMISE** study
- Join our interactive experience

MEET THE EXPERTS



Ferdinando D'Amico

*IRCCS Ospedale San Raffaele
Milan, Italy*



Axel Dignass

*Agaplesion Markus Hospital
Frankfurt, Germany*

Available online via recording



Silvio Danese

*IRCCS Ospedale San Raffaele
Milan, Italy*

Learn more at www.ferring.com
or connect with us on:




SCAN ME


abbvie	Satellite Symposium 2a Organiser: AbbVie Meeting room: Plenary Hall/Hall B
19:00 - 20:00	Start on the right path in Ulcerative Colitis J. Torres, Loures, Portugal
19:00 - 19:03	Welcome and introduction J. Torres, Loures, Portugal
19:03 - 19:18	Shining a light on disease control J. Torres, Loures, Portugal
19:18 - 19:33	Spotlight on IL-23 and JAK inhibitors in UC C. Ma, Calgary, Canada
19:33 - 19:48	Case based approach to illuminate the right path T. Raine, Cambridge, United Kingdom
19:48 - 19:58	Faculty Q&A All faculty led by Joana Torres, Loures, Portugal
19:58 - 20:00	Summary and close J. Torres, Loures, Portugal

ALFASIGMA	Satellite Symposium 2d Organiser: Alfasigma Meeting room: A4
19:00 - 20:00	Moderately active UC in the spotlight S. Vermeire, Leuven, Belgium
19:00 - 19:03	Welcome and introduction S. Vermeire, Leuven, Belgium
19:03- 19:13	Shining light on UC disease severity A. Walsh, Oxford, United Kingdom
19:13 - 19:28	Enlightened decisions: Right patient, right treatment, right time S. Vermeire, Leuven, Belgium Y. Zabana, Terrassa, Spain
19:28 - 19:43	Real-world evidence lighting the way: Insights into filgotinib S. Vermeire, Leuven, Belgium A. Walsh, Oxford, United Kingdom
19:43 - 19:58	Bright horizons: Assessing the future for patients with moderately to severely active disease, with Q&A session S. Vermeire, Leuven, Belgium A. Walsh, Oxford, United Kingdom Y. Zabana, Terrassa, Spain
19:58 - 20:00	Summary and close S. Vermeire, Leuven, Belgium

Friday, February 21, 2025

 MSD	Satellite Symposium 4a Organiser: Merck – MSD Meeting room: Plenary Hall/Hall B
19:00 - 20:00	<i>We can do better: Striving toward optimal care of the patient with Inflammatory Bowel Disease</i> R. Atreya, Erlangen, Germany
19:00 - 19:03	<i>Welcome and opening remarks</i> R. Atreya, Erlangen, Germany
19:03- 19:19	<i>Closing the gap: Current treatment of Inflammatory Bowel Disease and the pursuit of optimal care</i> B. Sands, New York, United States
19:13 - 19:35	<i>Confronting the consequences: Fibrostenosis and other complications from suboptimal control of Inflammatory Bowel Disease</i> F. Rieder, Cleveland, United States
19:35 - 19:51	<i>Navigating the patient journey: A personal conversation on living with IBD</i> R. Saldaña, Brussels, Belgium M. Dubinsky, New York, United States
19:51 - 20:00	<i>Q & A and closing remarks</i> R. Atreya, Erlangen, Germany

Johnson & Johnson	Satellite Symposium LS1 Organiser: Johnson & Johnson Meeting room: Plenary Hall/Hall B
12:45 - 13:25	<i>Expanding the universe in IBD: Going beyond in Ulcerative Colitis</i> T. Raine, Cambridge, United Kingdom S. Vermeire, Leuven, Belgium
12:45 - 12:48	<i>Welcome and introduction</i> T. Raine, Cambridge, United Kingdom
12:48 - 12:53	<i>Pushing the boundaries in IBD with IL-23</i> R. Atreya, Erlangen, Germany
12:53 - 13:07	<i>A new horizon: Evolving treatment strategies for Ulcerative Colitis</i> R. Atreya, Erlangen, Germany S. Vermeire, Leuven, Belgium
13:07 - 13:22	<i>Centre of the universe: Creating impact for patients in IBD</i> T. Raine, Cambridge, United Kingdom Moderator: S. Vermeire, Leuven, Belgium
13:22 - 13:25	<i>Summary and close</i> S. Vermeire, Leuven, Belgium

	Satellite Symposium LS2 Organiser: Celltrion Meeting room: Parallel Hall/A7
12:45 - 13:25	Early Intervention in IBD: Unlocking the potential of timely advanced treatment J.-F. Colombel, New York, United States
12:45 - 12:55	Why does early treatment matter? J.-F. Colombel, New York, United States
12:55 - 13:10	Proof of concept: Clinical importance of early treatment N. Noor, Cambridge, United Kingdom
13:10 - 13:20	Potential benefits of early treatment with Infliximab SC and other biologics J.-F. Colombel, New York, United States
13:20 - 13:25	Panel discussion: Future implications J.-F. Colombel, New York, United States N. Noor, Cambridge, United Kingdom

	Satellite Symposium LS3 Organiser: Takeda Meeting room: A8
12:45 - 13:25	From mucosal healing to disease clearance: Navigating the path to disease modification in UC P. Irving, London, United Kingdom
12:45 - 12:47	Welcome and introduction P. Irving, London, United Kingdom
12:47 - 12:55	Changing paradigms in UC management: Focusing on the patient P. Irving, London, United Kingdom
12:55 - 13:05	What have we learned from real-world evidence over the long-term? C. Lees, Edinburgh, United Kingdom
13:05 - 13:15	Treatment targets and disease clearance: What is the VERDICT now? V. Jairath, London, Canada
13:15 - 13:23	Audience Q&A All faculty
13:23 - 13:25	Summary and close P. Irving, London, United Kingdom

**BACK TO
THE FUTURE**



Friday, February 21, 2025
Room Helsinki 1

Conventional therapies continue to play a vital role in the treatment of IBD today and will remain important in the future. This symposium offers a valuable opportunity to revisit these established treatments with a fresh perspective and to explore evidence-based strategies for optimizing patient outcomes.



Tips and tricks for optimizing conventional therapy
Prof. Stephan Vavricka, Center for Gastroenterology and Hepatology, Zürich, Switzerland



**Optimized management of ulcerative proctitis:
A case study**
Prof. Janneke van der Woude, Radboud University Medical Center, Nijmegen, The Netherlands



**Avoiding over- and under-treatment:
Knowing when to switch**
Prof. Torsten Kucharzik, Municipal Hospital of Lüneburg, Germany

We look forward to seeing you there!

Abbreviation: IBD: inflammatory bowel disease.



Organized by Dr. Falk Pharma GmbH

General information:

The (invitation to the) event does not constitute an inducement to purchase, supply, sell, prescribe and/or use any products from our company and/or affiliated companies and is being carried out irrespective of such decisions made by you or your employer. The speakers and the scientific organizer will disclose any conflicts of interest to the participants during the event. Please check whether you need to obtain your employer's permission to attend the event. If you attend the event, Dr. Falk Pharma GmbH will assume that you have received the required employer's permission. This programme is not affiliated with ECCO. Paid advertisement by Dr. Falk GmbH.

Dr. Falk Pharma GmbH
Leinenweberstrasse 5
79108 Freiburg,
Germany

Tel: +49 761 1514 0
Fax: +49 761 1514 379
E-mail: zentrale@
drfalkpharma.de



Satellite Symposium LS4
Organiser: Eli Lilly & Company
Meeting room: A4

12:45 - 13:25 **Setting new standards in long-term remission with Mirikizumab in UC**
 A. Dignass, Frankfurt, Germany

12:45 - 12:55 **Focusing on what matters for UC Patients**
 A. Dignass, Frankfurt, Germany

12:55 - 13:05 **Early and sustained efficacy of Mirikizumab over 3 years**
 A. Armuzzi, Milan, Italy

13:05 - 13:15 **From trial to practice: Mirikizumab, beyond relief**
 A. Walsh, Oxford, United Kingdom

13:15 - 13:25 **Q&A**



Satellite Symposium LS5
Organiser: Dr. Falk Pharma
Meeting room: Helsinki 1

12:45 - 13:25 **Back to the future: Unveiling the power of established drugs**
 S. Vavricka, Zürich, Switzerland

12:45 - 12:50 **Welcome & intro**
 S. Vavricka, Zürich, Switzerland

12:50 - 13:58 **Tips and tricks for optimising conventional therapy**
 S. Vavricka, Zürich, Switzerland

13:58 - 13:06 **Optimized management of ulcerative proctitis: A case study**
 J. van der Woude, Rotterdam, The Netherlands

13:06 - 13:14 **Avoiding over – and under – treatment: Knowing when to switch**
 T. Kucharzik, Lüneburg, Germany

13:14 - 13:25 **Discussion, summary & close**
 All faculty

Industry sponsored Medical/Product Theatres

Thursday, February 20, 2025 – Medtronic

Medtronic	<i>Medical/Product Theatre PT1-Organiser: Medtronic Meeting room: Helsinki 1</i>
14:00 - 14:20	<i>Panenteric capsule endoscopy as treat-to-target treatment guide in quiescent Crohn's Disease – The CURE-CD randomised controlled trial</i> S. Ben-Horin, Tel-Aviv, Israel
14:00 - 14:20	<i>Methods and goals Outcomes and conclusions Potential influence on clinical practice</i>

Thursday, February 20, 2025 – Abivax

ABIVAX	<i>Medical/Product Theatre PT2-Organiser: Abivax Meeting room: Helsinki 2</i>
14:00 - 14:20	<i>Learn more about obefazimod – An oral, once daily investigational treatment with a novel mechanism of action in phase 3 clinical trials for Ulcerative Colitis</i> S. Danese, Milan, Italy
14:00 - 14:02	<i>Welcome and session objectives</i> S. Danese, Milan, Italy
14:02- 14:07	<i>How does it work? – Exploring Obefazimod's novel mechanism of action</i> S. Danese, Milan, Italy
14:07- 14:13	<i>What is the evidence? – Phase 2b clinical data highlights</i> S. Danese, Milan, Italy
14:13- 14:15	<i>What's next? – Advancing ABTECT Phase 3 program forward</i> S. Danese, Milan, Italy
14:15- 14:20	<i>Questions and answers</i>

Friday, February 21, 2025 – Eli Lilly & Company

 <small>A MEDICINE COMPANY</small>	Medical/Product Theatre PT3-Organiser: Eli Lilly & Company Meeting room: Helsinki 1
10:35 - 10:55	Mirikizumab in UC clinical practice: A long-term perspective Y. Zabana, Terrassa, Spain I. Blumenstein, Frankfurt, Germany
10:35 - 10:40	The role of Mirikizumab in the long-term UC management Y. Zabana, Terrassa, Spain
10:40 - 10:45	Mirikizumab in the UC treatment landscape: From trials to real-life I. Blumenstein, Frankfurt, Germany
10:45- 10:55	Discussion and Q&A

Friday, February 21, 2025 – Roche

	Medical/Product Theatre PT4-Organiser: Roche Meeting room: Helsinki 2
10:35 - 10:55	New Frontiers in IBD: TL1A Inhibition – From mode of action to clinical application R. Panaccione, Calgary, Canada J.-F. Colombel, New York, United States
10:35 - 10:40	The remaining unmet medical need in IBD R. Panaccione, Calgary, Canada J.-F. Colombel, New York, United States
10:40- 10:45	Introduction & mechanism of action for TL1A R. Panaccione, Calgary, Canada J.-F. Colombel, New York, United States
10:45- 10:50	Mechanistic and clinical data for TL1A inhibition R. Panaccione, Calgary, Canada J.-F. Colombel, New York, United States
10:50- 10:55	Conclusions & outlook R. Panaccione, Calgary, Canada J.-F. Colombel, New York, United States

Industry exhibition

Opening hours

Thursday, February 20, 2025	10:30 - 18:00
Friday, February 21, 2025	08:00 - 18:00
Saturday, February 22, 2025	09:00 - 13:00

List of exhibitors & sponsors

Location: Hall 2.2 and Hall 4.2

Company	Booth number
<i>AbbVie</i>	24
<i>Abivax</i>	30
<i>Accord Healthcare GmbH</i>	31
<i>Adacyte Therapeutics, SL</i>	5
<i>Alfasigma S.p.a</i>	32
<i>Alimentiv B.V.</i>	29
<i>Amgen, Inc</i>	34
<i>BIOSYNEX Theradiag</i>	4
<i>Boehringer Ingelheim</i>	10
<i>BÜHLMANN Laboratories AG</i>	8
<i>CALPRO AS</i>	22
<i>Celltrion Inc.</i>	15
<i>Diasorin S.p.A.</i>	20
<i>Dr. Falk Pharma</i>	6
<i>Eli Lilly & Company</i>	23
<i>EOS2021 srl</i>	36
<i>EUROIMMUN AG</i>	17
<i>Ferring Pharmaceuticals</i>	35


Company	Booth number
<i>Immundiagnostik AG</i>	19
<i>Johnson & Johnson</i>	25
<i>La Lettre de l'Hépatogastroentérologue</i>	11
<i>metaX Institut für Diätetik GmbH</i>	3
<i>Motilent</i>	18
<i>MSD</i>	27
<i>Nestlé Health Science</i>	9
<i>Nordic Bioscience</i>	26
<i>Nutritional Therapy for IBD</i>	1
<i>Pfizer</i>	33
<i>Pharmacosmos</i>	21
<i>Preventis GmbH</i>	37
<i>PSI CRO</i>	2
<i>Roche</i>	7
<i>STADA Arzneimittel AG</i>	16
<i>Takeda Commercial</i>	14
<i>Takeda Medical</i>	13
<i>Tillotts Pharma AG</i>	28

Exhibiting societies

Location: Hall 7, Entrance Lobby

Society	Booth number
<i>European Federation of Crohn's and Ulcerative Colitis Associations – EFCCA</i>	A
<i>International Bowel Ultrasound Group – IBUS</i>	B
<i>The China Crohn's & Colitis Foundation – CCCF</i>	C
<i>United European Gastroenterology – UEG</i>	D

Hall 2.2




Poster Exhibition



Cash Catering

Hall 4.2



ECCO Corporate Members

(as of January 24, 2025)

ECCO gratefully acknowledges the support of the following ECCO Corporate Members:

abbvie

ALFASIGMA 

AMGEN®

 BÜHLMANN

 Bristol Myers
Squibb®

 CELLTRION

 DyFalk

 FERRING
PHARMACEUTICALS



ECCO'25 Cooperation Partner

VISIT BERLIN 
CONVENTION OFFICE

Imprint

Publisher

ECCO – European Crohn's and Colitis Organisation
Austrian Register of Associations: N° 468755685
Zentrales Vereinsregister (ZVR)-Zahl: N° 468755685
OCEAiN GmbH

Ungargasse 6/13, 1030 Vienna

Phone: +43-(0)1-710 22 42

E-Mail: ecco-congress@ecco-ibd.eu

Web: www.ecco-ibd.eu

Photo material

Rainer Mirau www.rainermirau.at

Video material:

Proddigi www.proddigi.com

Metafusion www.meta-fusion.com



You are invited to two Takeda-organized symposia during ECCO 2025

Early vs Personalized Treatment for Crohn's Disease: Is There More Than One Path to Disease Control?

THURSDAY, FEBRUARY 20, 2025 | 11:00-12:00 (CET)
ROOM A8, CITYCUBE MESSE BERLIN, GERMANY



GEERT D'HAENS
(CHAIR)



SHOMRON
BEN-HORIN



PARAMBIR
DULAI

Refreshments provided

From Mucosal Healing to Disease Clearance: Navigating the Path to Disease Modification in UC

FRIDAY, FEBRUARY 21, 2025 | 12:45-13:25 (CET)
ROOM A8, CITYCUBE MESSE BERLIN, GERMANY



PETER IRVING
(CHAIR)



CHARLIE
LEES



VIPUL
JAIRATH

Refreshments provided

Visit our medical booth **#13**

Paid advertisement by Takeda. These symposia are initiated, organized, and funded by Takeda and are intended for healthcare professionals registered for ECCO 2025 only.

These symposia are not affiliated with ECCO 2025.

© 2025 Takeda Pharmaceuticals International AG.

All rights reserved. Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceuticals Company Limited.

January 2025 | W-MEDMAT-115151





European
Crohn's and Colitis
Organisation

Stockholm
Sweden

Inflammatory Bowel Diseases

Announcement 2026

STH

21st Congress of ECCO
Stockholm
February 18-21, 2026

- Stockholmsmässan, Stockholm
- EACCME applied
- Register at www.ecco-ibd.eu/ecco26

www.ecco-ibd.eu